Related Experiment Video
Updated: Nov 6, 2025
09:34
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
2.0K
Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis
Stefanie Krug1, Sadiya Parveen1, William R Bishai1
1Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Frontiers in Immunology
|May 6, 2021
Summary
Controlling tuberculosis (TB) requires balancing the immune response. Modulating pro- and anti-inflammatory pathways may improve TB treatment and reduce lung damage.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Background:
- Tuberculosis (TB) is caused by Mycobacterium tuberculosis.
- A balanced host immune response is crucial for containing TB infection.
- Dysregulated inflammation can lead to lung damage and prolonged treatment.
Purpose of the Study:
- To review host-directed therapies for TB targeting immune responses.
- To explore the potential of modulating inflammation in TB treatment.
- To highlight repurposed drugs for TB therapy.
Main Methods:
- Review of pre-clinical models evaluating host-directed TB therapies.
- Analysis of immune response modulation (pro- and anti-inflammatory).
- Focus on drug repurposing for TB treatment.
Main Results:
- Host immune responses involve both pro- and anti-inflammatory mechanisms.
- Mycobacterium tuberculosis manipulates host immunity for its benefit.
- Targeting immune responses can potentially improve TB outcomes.
Conclusions:
- Modulating the timing and levels of immune responses is key in TB.
- Host-directed therapies targeting inflammation show promise for TB treatment.
- Repurposing existing drugs could enhance future TB therapeutic strategies.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
277
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
277
01:29Inflammatory Bowel Disease IV: Pharmacological Management
259
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
259
01:28Pulmonary Tuberculosis V
295
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
295
01:29Pulmonary Tuberculosis I
449
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
449
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
300
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
300
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
266
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
266